One thing I do know is that P/R of a company is absolutely an integral part of all corporate playbooks. Success of any venture is the ability to promote products no matter what. Relying on a governmental agency to advance it is laughable imo.
Paint the canvas with a much wider brush is the advice I would convey to the CEO. Being a graduate of a prestigious institution he should have had that embedded in his grey metter. FOR SURE!
Bio..let me ask you..you seem quite bright...What does XXII have to market? They are tied up on an FDA application. Hemp and marijuana are not legal in the U.S. yet. They have resources and he made a great sale of the Aurora position. We have nothing but patents at the moment. The minute we get the PMTA approved then we can move. All potential interested parties are waiting just like us for the FDA to move. They are on the clock too. But I can't see what XXII can do on the promotion front as they have nothing yet to promote. I know Henry has met with a lot of potential players. Altria bought a bunch of our Spectrums last year. BTI saw our stuff first hand. Monasanto?? Scotts??
The pharma companies are potential investors but they are not going to move. We dropped the prescription play after July 2017.
If someone can suggest a place where we should expend resources and create revenue I would love to hear it.
News 
Market Data 
Discover 
AI
